Dependencia de alcohol y sistema serotoninérgico: Implicaciones terapéuticas

Medicina Clinica

Volumn 109, Issue 15, 1997, Pages 599-605

  Arranz, Belén ^a,b   San, Luis ^a,b,c  

^a HOSPITAL DEL MAR   (Spain)

^b Complejo Asistencial Salud Mental B ^*  (Spain)

^c Benito Menni Complex Assistencial en Salut Mental   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VIQUALINE; ZIMELDINE;

ALCOHOLISM; ARTICLE; CLINICAL TRIAL; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; DRUG MECHANISM; HUMAN; SEROTONINERGIC SYSTEM;

ALCOHOLISM; BRAIN CHEMISTRY; CLINICAL TRIALS; ETHANOL; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0030731883     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Freixa F. Estado actual de los problemes del alcohol en España. En: Casas M, Gutiérrez M, San L, editores. Psicopatología y alcoholismo. Barcelona: Ediciones en Neurociencias, 1994; 243-283.
2. San L Farmacoterapia en alcoholismo. Med Clin (Barc) 1986; 87: 688-690.
3. Miller NS, Gold MS. A hypothesis for a common neurochemical basis for alcohol and drug disorders. Psychiatr Clin North Am 1993; 16: 105-117.
4. Liljequist S, Borg S. Pharmacotherapy of alcohol and drug dependence. Curr Opin Psychiatry 1993; 6: 419-423.
5. Koob GF, Rassnick S, Heinrichs S, Weiss F. Alcohol, the reward system and dependence. EXS 1994; 71: 103-114.
6. Roy A, Virkkunen M, Linnoila M. Reduced central serotonin turnover in a subgroup of alcoholics? Prog Neuropsychopharmacol Biol Psychiatry 1987; 11: 173-177.
7. Siegal FL, Roach MK, Pomeroy LR. Plasma aminoacid patterns in alcoholism: the effects of ethanol loading. Proc Natl Acad Sci USA 1964; 51: 605-611.
8. Branchey L, Shaw S, Lieber CS. Ethanol impairs tryptophan transport into the brain and depresses serotonin. Life Sci 1981; 29: 2.751-2.755.
9. Hjorth M, Bille M, Smith DF. Serum tryptophan levels in alcoholics. Drug Alcohol Depend 1981; 7: 157-161.
10. Diehl AME, Mitchell MC, Herlong HF, Potter JJ, Wacker L, Mezey E. Changes in plasma amino acids during sobriety in alcoholic patients with and without liver disease. Am J Clin Nutr 1986; 44: 453-460.
11. Banki CM. 5-Hydroxytryptamine content of the whole blood in psychiatric illness and alcoholism Acta Psychiatr Scand 1978; 57: 232-238.
12. Rolf RH, Matz DR, Brune GG. Serotonin metabolism in chronic alcoholism. Experientia 1978; 34: 74-75.
13. Bailly D, Vignau J, Lauth B, Racadot N, Beuscart R, Servant D, Parquet PJ. Platelet serotonin decrease in alcoholic patients. Acta Psychiatr Scand 1990; 81: 68-72.
14. Bailly D, Vignau J, Raacadot N, Beuscart R, Servant D, Parquet PJ. Platelet serotonin levels in alcoholic patients: changes related to physiological and pathological factors. Psychiatry Res 1993; 47: 57-88.
15. Simonsson P, Berglund M, Oreland L, Moberg AL, Ailing C. Serotonin-stimulated phosphoinositide hydrolysis in patients from post-withdrawal alcoholics. Alcohol Alcohol 1992; 27: 607-612.
16. Takahashi S, Yamane H, Kondo H, Tani N, Kato N. CSF monoamine metabolites in alcoholism: A comparative study with depression. Folia Psychiatr Neurol 1974; 28: 347-354.
17. Ballenger J, Goodwin F, Major L, Brown G. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry 1979; 36: 224-227.
18. Banki CM. Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. J Neural Transm 1981; 50: 89-101
19. Banki CM, Arato M, Papp Z, Kurcz M. Biochemical markers in suicidal patients. J Affective Disord 1984; 6: 341-350.
20. Helander A, Beck O, Jacobsson G, Lowenmo C, Wikstrom T. Time course of ethanol-induced changes in serotonin metabolism. Life Sci 1993; 53: 847-855.
21. Virkkunen M, Rawlings R, Tokola R, Poland R, Giudotti A, Nemeroff C et al. CSF biochemistries, glucose metabolism and diurnal activity rhythms in alcoholic, violent offenders, fire setters and healthy volunteers. Arch Gen Psychiatry 1994; 51: 20-27.
22. Baccino E, Menez JF, Caroff J, Henry A, Mottier D, Floch H. Changes in serotonin uptake and storage in platelets during withdrawal of alcoholics with hepatopathy [resumen]. Alc Alcohol 1987; 22: A21.
23. Boismare F, Lhuintre JP, Daoust M, Moore N, Saligaut C, Hillemand B. Platelet affinity for serotonin is increased in alcoholics and former alcoholics A biological marker for dependence? Alcohol Alcohol 1987; 22: 155-159.
24. Neiman J, Beving H, Malmgren R. Platelet uptake of serotonin (5-HT) during ethanol withdrawal in male alcoholics. Thromb Res 1987; 46: 803-809.
25. Lhuintre JP, Boismare F, Daoust M. Increased platelet affinity for serotonin: a marker for alcohol dependence. En: Kuriyama K, Takada A. lahii H, editores. Biomedical and Social Aspects of Alcohol and Alcoholism, Excerpta Medica International Series. Amsterdam: Elsevier, 1988; 557-560.
26. Daoust M, Lhuintre JP, Ernouf D, Legrand E, Breton P, Boucly P. Ethanol intake and 3H-serotonin uptake. II: A study in alcoholic patients using platelets 3H-paroxetine binding. Life Sci 1991; 48: 1.977-1.983.
27. Ernouf D, Compagnon P, Lothion P, Narcisse G, Bernard JY, Daoust M. Platelets 3H 5-HT uptake in descendants from alcoholic patients: a potential risk factor for alcohol dependence? Life Sci 1993; 52: 989-995.
28. Patkar AA, Naik PC, Marsden CA, McLean PC, Kendall DA. 3H-Imipramine binding in type I and type II alcoholism. Human Psychopharmacol 1995; 10: 315-320.
29. Mellerup ET, Been P, Lauritzen L, Lunde M, Plenge P. Platelet paroxetine binding in alcoholics. Alcohol Alcohol 1993; 27: 603-606.
30. Simonsson P, Ailing C. The 5-hydroxytryptamine stimulated formation of inositol phosphate is inhibited in platelets from alcoholics. Life Sci 1988; 42: 385-391.
31. Naranjo CA, Bremmer KE. Serotonin-altering medications and desire, consumption and effects of alcohol-treatment implications. EXS 1994; 71: 209-219.
32. Naranjo CA, Kadlec KE. Possible pharmacological probes for predicting and preventing relapse in treated alcoholics. Alcohol Alcohol 1991; 1 (Supl 1): 523-526.
33. Pihl RO, Young SN, Ervin FR, Plotnick S. Influence of tryptophan availability on selection of alcohol and water by men. J Stud Alcohol 1987; 48: 260-264.
34. George DT, Lindquist T, Rawlings RR, Eckardt MJ, Moss H, Mathis C et al. Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa. Clin Pharmacol Ther 1992; 52: 553-560.
35. Hitzig P. Combined dopamine and serotonin agonists: a synergistic approach to alcoholism and other addictive behaviors. Mod Med J 1993; 42: 153-156.
36. Benkelfat C, Murphy DL, Hill JL, George DT, Nutt D, Linnoila M Ethanollike properties of the serotonergic partial agonist m-Clorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatr 1991; 48: 383.
37. Krystal JH, Webb E, Cooney N, Kranzler H, Charney DS. Specificity of ethanol-like effects effected by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry 1994; 51: 898-911.
38. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacological Rev 1994; 46: 157-203.
39. San L, Torrens M. Alcohol y ansiedad. Monografías de Psiquiatría 1994; 1: 26-33.
40. Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22: 49-59.
41. Kranzler HR, Meyer RE. Open trial of buspirone in alcoholics. J Clin Psychopharmacol 1989; 9: 379-380.
42. Kranzler HR, Burleson JA, Del Broca FK, Babor TF, Korner P, Brown J et al. Buspirone treatment of anxious alcoholics. Arch Gen Psychiatry 1994; 51: 720-731.
43. Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992; 12: 19-26.
44. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A. A placebo-controlled trial of buspirone in anxious inpatient patients. Alcohol Clin Exp Res 1992; 16: 1.007-1.013.
45. Cloninger CR. Neurogenetic adaptative mechanisms in alcoholism. Science 1987; 236: 410-416.
46. Monti JM, Alterwain P. Ritanserin decreases alcohol intake in chronic alcoholics. Lancet 1991; 337: 60.
47. Naranjo CA, Poulos CX, Umana M, Lanctôt KL, Bremner KE, Kwok M. Effects of ritanserin (R) on desire to drink and consummatory behavior (CB) in heavy alcohol drinkers [resumen]. Clin Pharmacol Ther 1993; 53: 176.
48. Naranjo C, Poulos CX, Lanctot KL, Bremner KE, Kwok M, Umana M. Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects. Addiction 1995; 90: 893-905.
49. Costall B, Jones BJ, Kelly ME, Nayor RJ, Onaivi ES, Tyers MD. Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol Biochem Behav 1990; 36: 97-104.
50. Wozniak KM, Pert A, Linnoila M. Antagonism of 5-HT3 receptors attenuates the effects of ethanol on extracellular dopamine. Eur J Pharmacol 1990; 187: 287-289.
51. Grant KA, Barrett JE. Blockade of the discriminative stimuls effects of ethanol with 5-HT3 receptor antagonists. Psychopharmacology 1991; 104: 451-456.
52. Toneatto T, Romach MK, Sobell LC, Sobell MB, Somer GR, Sellers EM. Ondansetron, a 5-HT3 antagonist, reduces alcohol consumption in alcohol abusers [resumen]. Alcohol Clin Exp Res 1991; 15: 382.
53. Sellers EM, Romach MK, Frecker RC, Higgins GA. Efficacy of the 5-HT3 antagonist ondansetron in addictive disorders. En: Racagni G, Brunello N, Fukudo T, editores. Proceedings of the 5th World Congress of Biological Psychiatry. Amsterdam: Elsevier Science Publishers BV, 1991; 2: 894-897.
54. Johnson BA, Campling GM, Griffiths P, Cowen PJ. Attenuation of some alcohol-induced mood changs and desire to drink by r-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology 1993; 112: 142-144.
55. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18: 879-885.
56. Engel JA, Enerback C, Fahlke C, Hulthe P, Hard E, Johannessen K et al. Serotonergic and dopaminergic involvement in ethanol intake. En: Naranjo CA, Sellers EM, editores. Novel pharmacological interventions for alcoholism. Nueva York: Springer-Verlag, 1992; 68-82.
57. Given MB, Longenecker GL. Characteristics of serotonin uptake and release by platelets En: Longenecker GL, editor. The platelets, physiology and pharmacology. Nueva York, Londres: Academic Press, 1985; 463-479.
58. Bäckström I, Bergstrom M, Marcusson J. High affinity 3H-paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 1989; 486: 261-258.
59. Arranz B, Rosel P. Los receptores de imipramina en la actualidad. IMP-Psiquiatría 1991; 3: 170-172.
60. Arranz B, Marcusson J. Characterization of the human brain 5-HT uptake site with [3H]paroxetine and [3H]citalopram. J Neural Transm [Gen-Sect] 1994; 97: 27-40.
61. Roy A, Linnoila M, Alcoholism and suicide. Suicide Life Threat Behav 1985; 16: 244-273.
62. Extein IL, Gold MS. Hypothesized neurochemical models for psychiatric syndromes in alcohol and drug dependence. J Addict Dis 1993; 12: 29-43.
63. Gill K, Amit Z. Serotonin uptake blockers and voluntary alcohol consumption. A review of recent studies. Recent Dev Alcohol 1989; 7: 225-248.
64. Van Harten JJ, Stevens LA, Raghoebar M, Holland RL, Wesnes K, Cournot A. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther 1992; 52: 427-435.
65. Suranyi-Cadotte B, Dongier M, Lafaille F, Luthe L. Platelets of alcoholics, and of subjects genetically at risk for alcoholism, share the same abnormality of imipramine binding sites. Br J Addict 1989; 84: 437-445.
66. Gentsch C, Lichsteiner M, Gastpar M, Gastpar G, Feer H. 3H-Imipramine binding sites in platelets of hospitalized psychiatric patients. Psychiatry Res 1985; 14: 177-187.
67. Tollefson GD. Serotonin and alcohol: interrelationships. Psychopathology 1989; 22: 37-48.
68. Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sánchez-Craig M, Sykora K. Zimelidine-induced variations in alcohol intake by non-depressed heavy drinkers. Clin Pharmacol Ther 1984; 35: 374-381.
69. Amit Z, Brown Z, Sutherland Z. Reduction in alcohol intake in humans as a function of treatment with zimelidine: implications for treatment. En: Naranjo CA, Sellers EM, editores. Research advances in new psychopharmacological treatments for alcoholism. Amsterdam: Excerpta Medica, 1985; 189-198.
70. Naranjo CA, Sellers EM, Jullivan JT, Woodley DV, Kadlec K, Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987; 41: 266-274.
71. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Citalopram decreases desirability, liking and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 1992; 51: 729-739.
72. Naranjo CA, Bremner KE, Lanctot KL. Effects of citalopram and brief psychosocial intervention on alcohol intake, dependence and problems. Addiction 1995; 90: 87-99.
73. Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G, Sellers EM. Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther 1989; 46: 301-309.
74. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992; 16: 261-265.
75. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 1990; 47: 490-498.
76. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol 1994; 9: 163-172.
77. Gerra G, Caccavari R, Delsignore R, Bocchi R, Fertonani G, Passeri M. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familiar and nonfamiliar alcohol patients. Curr Ther Res 1992; 52: 291-295.
78. Cornelius JR, Salloum IM, Cornelius MD, Perel JM, Thase ME, Ehler JG et al. Fluoxetine trial in suicidal depressed alcoholics. Psychopharmacol Bull 1993; 29: 195-199.
79. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391-397.
80. Kranzler HR, Del Boca FK, Korner P, Brown J. Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism. J Subst Abuse Treat 1993; 10: 283-287.
81. Fuller RW, Wong DT. Serotonin reuptake in vitro and in vivo. J Clin Psychopharmacol 1987; 7: 36-43.
82. Lemberger L, Rowe H, Carmichael R. Fluoxetine, a selective serotonin uptake inhibitor. Clin Pharmacol Ther 1978; 23: 421-429.
83. Wamsley JK, Byerley WF, McCabe RT. Receptor alterations associated with serotonergic agents: an autoradiographic analysis. J Clin Psychiatry 1987; 48: 19-25.
84. Blundell JE. Serotonin and appetite. Neuropharmacology 1984; 23: 1.537-1.551.
85. Naranjo CA, Sellers EM, Lawrin MO. Modulation of ethanol intake by serotonin uptake inhibitors. J Clin Psychiatry 1986; 47: 16-22.
86. Gorelick DA. Serotonin uptake blockers and the treatment of alcoholism. En: Galanter M, editor. Recent developments in alcoholism: treatment research. Nueva York: Plenum Press, 1989; 7: 267-281.